Mutant Factor VIII Enhances Secretion and Reduces Vector Dose
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy techniques for treating hemophilia A face challenges in achieving sufficient expression levels of factor VIII protein, leading to high doses of viral vectors and immune system activation due to inefficient secretion and potential immunogenicity.
Innovation Solution
Development of recombinant human factor VIII mutants with specific amino acid substitutions, such as I86V, Y105F, Q117H, G132K, H134Q, M147T, and L152P, which enhance expression and secretion levels, along with B-domain deletion and fusion of A2 and A3 domains, to improve protein stability and reduce immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type factor VIII is used in gene therapy, then the protein can be expressed in host cells, but the expression level is insufficient and requires high doses of viral vector
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions (I86V, Y105F, Q117H, G132K, H134Q, M147T, L152P) into the factor VIII protein sequence. These mutations alter the protein's properties to enhance its secretion efficiency and expression level, thereby reducing the required viral vector dose while maintaining therapeutic efficacy.
2Productivity
If wild-type factor VIII is expressed, then protein production occurs, but secretion efficiency is very low
Solution Approach 1:
The patent modifies the factor VIII protein by introducing specific amino acid substitutions that directly affect secretion efficiency. The mutations at positions I86, Y105, Q117, G132, H134, M147, and L152 are designed to optimize the protein's interaction with cellular secretion pathways, transforming it from a poorly secreted wild-type protein to a highly secreted recombinant protein suitable for therapeutic production.
3Reliability
If viral vectors are used to deliver factor VIII gene, then in vivo protein expression is achieved, but immune system activation occurs due to viral protein coating
Solution Approach 1:
The patent extracts and removes the immunogenic viral protein coating from the vector surface while maintaining the viral vector's ability to deliver the factor VIII gene. By using modified viral vectors with reduced or eliminated immunogenic proteins, the system achieves in vivo protein expression without triggering harmful immune responses, thus resolving the contradiction between delivery effectiveness and safety.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
In one aspect, present invention provides a recombinant mutant human factor VIII having increased expression and/or secretion as compared to wild-type factor VIII. In certain embodiments, the recombinant factor VIII includes one or more amino acid substitution(s) selected from the group consisting of 186, Y105, A108, D115, Q117, F129, G132, H134, M147 and L152. In other aspects, the present invention provides FVIII encoding nucleic acids, FVIII-expression vectors, as well as methods of using the modified FVIII genes in the treatment of FVIII deficiencies, such as hemophilia A.